A Phase I Study to Assess the Safety, Pharmacokinetics, and Potential Effects of Amrubicin on the QT/QTc Interval in Cancer Patients With Advanced Solid Tumors.

• Status: Completed
• Trial end date: 2011-05-01

Summary

The purpose of the study is to determine whether amrubicin is safe and effective in the treatment of patients with advanced solid tumors. The study will assess the pharmacokinetics of the amrubicin and if it has an effect on the heart.

• Phase: Phase 1

Details

• Lead Sponsor: Celgene; Celgene Corporation
• Treatments: Amrubicin